West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year. 2023 marks West’s 100-year milestone of innovation and the critical role it continues to play in healthcare and the patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com. | West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 47 billion components and devices each year. In 2023, West commemorated a century of groundbreaking innovation that has shaped the landscape of healthcare and impacted the lives of patients around the world. This milestone served as a testament to West’s commitment to revolutionize drug delivery and enhance the overall patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com. | West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com.
Virchow Biotech (P) Ltd
Incorporated in 2001, Virchow Biotech (P) Limited (VBPL), the bio pharmaceutical company of the Virchow group focuses on the manufacturing of a wide range of biologicals and bio-generics by genetic engineering, classical fermentation, or extraction technologies.
Vetter
Vetter is a global leading contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the United States. The company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com. | Vetter is a global leading contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the United States. The company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and compliance. Great importance is also given to social responsibility including environmental protection and sustainability. | Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,300 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Valpharma International S.p.A.
Valpharma Group SpA is an European pharmaceutical company leader in pharmaceutical development and contract manufacturing of oral FDF solid dosage medicines and nutraceuticals, with more than 45 years expertise in commercial supply in more than 70 markets. Our plants are authorized to manufacture (IMP and commercial) powders, granulates, film-coated- not film-coated tablets (FDF), pellets bulk or capsules (FDF). Dossiers: Melatonine ER Apixaban IR Gliclazide SR Diltiazem SR In development Semaglutide IR Upadacitinib ER Mirabegron ER
UNITHER PHARMACEUTICALS
Unither Pharmaceuticals is a pharmaceutical subcontractor specializing in the development and manufacturing of unit-dose and multidose liquid formulations (including eye drops, saline solutions, asthma medications in BFS unit doses, and oral liquid stick-packs) for originator pharmaceutical companies and generic manufacturers. With 2,300 employees and eight manufacturing plants across France, the United States, Brazil and China, as well as an R&D center in France, Unither Pharmaceuticals reported sales of EUR 522 million in 2024. www.unither-pharma.com
TLC BioSciences
TLC BioSciences is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC was consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations every year until the company went private in 2021. | TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC is dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC BioSciences is a clinical‑stage biotechnology company advancing lipid‑engineered medicines across metabolic, orthopedic, and immune‑cell therapy. Our proprietary LipAD® family of platforms—including BioSeizer® sustained‑release technology, NanoX® active drug‑loading systems, and next‑generation targeted lipid nanoparticles (tLNP)—enables long‑acting, targeted, and programmable delivery for a wide range of therapeutic modalities. With a robust pipeline spanning once‑monthly GLP‑1 therapy (TLC518), late‑stage non‑opioid pain programs, and in‑vivo CAR‑T applications, TLC is committed to delivering medicines with improved efficacy, safety, and accessibility.
SiriusXT Ltd
SiriusXT has developed the only commercially-available laboratory instrument that is capable of non-destructively imaging the whole internal structure of intact cells or tissue slabs, with high natural contrast (label-free) and with nanometer-resolution. The microscope, called a Soft X-ray Microscope, uses an imaging modality that has been in use for over 30 years but which has only been available at six global, football stadium-sized, research facilities, called synchrotrons. SiriusXT has effectively miniaturized the synchrotron into a chamber measuring less than 3 feet in diameter, enabling the development of a table-top microscope. This means that the benefits of soft X-ray microscopy are now accessible 24/7, without having to wait for up to 12 months to get access to the synchrotron microscopes. Despite the very restricted access to the synchrotron-based microscopes many hundreds of peer-reviewed papers have been published by scientists working in disease research and therapeutic discovery where the images produced by the microscopes have helped in making significant advances in scientific state of the art. In biological research, Soft X-ray Microscopy can be used as a stand-alone cell and tissue structural imaging technique, where it can image sample thicknesses that are close to 50 times greater than can be imaged with electron microscopy. It can also be used in correlative imaging workflows, along with light and electron microscopy, to greatly increase (by a factor of over 20 times) the sample imaging throughput. Thirdly, it has been demonstrated that Soft X-ray Microscopy provides an effective means for tracking and validating the delivery of nanoparticle, carrying a cargo of therapeutics, vaccines or adjuvants, to targeted end points in cells. SiriusXT has commissioned its first commercial product, the SXT-100, in 2024 at a research university in Europe. It is now focused on introducing the SXT-100 to target customers in the US.
SiO2 Materials Science
SiO2 delivers a next-generation platform of primary drug containers—including vials, prefilled syringes (PFS), and cartridges—built on a patented tri-layer plasma coating applied to COP (Cyclic Olefin Polymer). This advanced barrier technology creates a unique hybrid: combining the inert, protective qualities of glass with the durability and design flexibility of plastic—without the limitations of either. Our containers are purpose-built for high-performance drug containment, offering superior compatibility and stability for today’s most sensitive and complex therapeutics. Engineered to meet the highest pharmaceutical standards, SiO2 containers offer: No silicone oil No breakage or delamination No extractables or leachables No heavy metal ions or needle adhesives No drug interactions or gas permeation Broad compatibility with extreme pH ranges and high-viscosity formulations All SiO2 containers are delivered in a fully validated ready-to-use (RTU) format and have been qualified across leading CDMO and pharma filling lines. With a robust IP portfolio of over 300 patents, our technology stands as a key differentiator in delivering innovation, compliance, and performance at scale.